Cabaletta Bio Inc (NASDAQ:CABA) has a beta value of 2.44 and has seen 0.46 million shares traded in the recent trading session. The company, currently valued at $65.00M, closed the recent trade at $1.33 per share which meant it lost -$0.05 on the day or -3.97% during that session. The CABA stock price is -1331.58% off its 52-week high price of $19.04 and -2.26% below the 52-week low of $1.36. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.93 million shares traded. The 3-month trading volume is 1.20 million shares.
The consensus among analysts is that Cabaletta Bio Inc (CABA) is Buy stock at the moment, with a recommendation rating of 1.36. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 5 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.66.
Cabaletta Bio Inc (NASDAQ:CABA) trade information
Sporting -3.97% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CABA stock price touched $1.33 or saw a rise of 20.83%. Year-to-date, Cabaletta Bio Inc shares have moved -41.41%, while the 5-day performance has seen it change -19.88%. Over the past 30 days, the shares of Cabaletta Bio Inc (NASDAQ:CABA) have changed -20.36%. Short interest in the company has seen 6.23 million shares shorted with days to cover at 5.3.
Wall Street analysts have a consensus price target for the stock at $14, which means that the shares’ value could jump 90.5% from the levels at last check today. The projected low price target is $3.0 while the price target rests at a high of $32.0. In that case, then, we find that the latest price level in today’s session is -2306.02% off the targeted high while a plunge would see the stock gain -125.56% from the levels at last check today.
Cabaletta Bio Inc (CABA) estimates and forecasts
The company’s shares have lost -68.78% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%. 5 have an estimated revenue figure of 5M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -20.35% over the past 5 years. Earnings growth for 2025 is a modest -5.28% while over the next 5 years, the company’s earnings are expected to increase by 4.92%.
CABA Dividends
Cabaletta Bio Inc is expected to release its next earnings report on 2025-Mar-30 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cabaletta Bio Inc (NASDAQ:CABA)’s Major holders
Insiders own 3.10% of the company shares, while shares held by institutions stand at 79.61% with a share float percentage of 82.16%. Investors are also buoyed by the number of investors in a company, with Cabaletta Bio Inc having a total of 152.0 institutions that hold shares in the company. The top two institutional holders are JENNISON ASSOCIATES LLC with over 5.55 million shares worth more than $41.49 million. As of 2024-06-30, JENNISON ASSOCIATES LLC held 11.2498% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 4.76 million shares as of 2024-06-30. The firm’s total holdings are worth over $35.58 million and represent 9.6469% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are T. Rowe Price Small-Cap Value Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. As of Dec 31, 2024, the former fund manager holds about 3.95% shares in the company for having 1.93 shares of worth $2.59 million while later fund manager owns 1.4 shares of worth $1.88 million as of Dec 31, 2024, which makes it owner of about 2.87% of company’s outstanding stock.
